Breaking News

European Court Orders Russia to Pay €1.87 Billion for Yukos Seizure
Tweet TWEET

Before the Bell Scans: Dynavax Technologies, Warner Chilcott, Avanir Pharma, and Actavis

 Before the Bell Scans: Dynavax Technologies, Warner Chilcott, Avanir Pharma,
                                 and Actavis

PR Newswire

LONDON, June 19, 2013

LONDON, June 19, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Drug manufacturers in the U.S., as well as globally, have been facing
increasing competition from generic drug makers following the expiration of
patents on several blockbuster drugs. In 2013 alone, patents on drugs with
annual sales of nearly $30 billion are set to expire. This will lead to
further generic competition. The "patent cliff" has created significant
challenges for drug manufacturers. The key for drug companies will be to boost
their product pipelines and collaborate with institutions and biotechnology
companies that have developed, or are developing, potential blockbuster drugs.
On Tuesday, June 18, 2013, shares in drug manufacturers and generic drug
companies ended mostly higher, tracking gains in the broader market. The major
movers in the sector included Dynavax Technologies Corporation (NASDAQ: DVAX),
Warner Chilcott Plc (NASDAQ: WCRX), Avanir Pharmaceuticals Inc. (NASDAQ:
AVNR), and Actavis Inc. (NYSE: ACT). All these companies are tracked by
AAAResearchReports.com. Free technical research on DVAX, WCRX, AVNR, and ACT
can be downloaded upon sign up at

http://www.aaaresearchreports.com/register/ 

Shares in Dynavax Technologies Corporation tumbled on Tuesday, extending their
losses from previous trading sessions. The company's shares hit a 52-week low
of $0.99 before finishing the day 5.45% lower at $1.04. A total of 6.57
million shares were traded, which is well above the daily average volume of
3.30 million. The drug manufacturer's shares have declined by over 13.30% in
the last three sessions, and so far this year, the stock has tumbled over
62.00%. Besides, the company's shares are currently trading 79.61% below their
52-week high. Sign up today to read free research report on DVAX at:

http://www.AAAResearchReports.com/DVAX061913.pdf

Warner Chilcott Plc's stock moved 0.33% higher yesterday, reversing some of
its recent losses. The company's shares traded between $19.64 and $19.88
before closing the day at $19.75 on a total of 3.44 million shares traded,
which is well below the daily average volume of 10.64 million. Shares of this
drug maker have dropped by nearly 1.40% in the last three sessions. Since the
start of 2013, the stock has gained over 68.00%, thus outperforming the S&P
500. The company's shares are currently trading well above their 50-day and
200-day moving averages. Register to download free technical analysis on WCRX
at:

http://www.AAAResearchReports.com/WCRX061913.pdf

Shares in Avanir Pharmaceuticals Inc. rose sharply on Tuesday, extending 
their gains from the previous market sessions. The company's shares hit an
intraday high of $4.62 before ending the day 2.10% higher at $4.61. It also
saw a total of 3.02 million shares traded which is well above the daily
average volume of 2.00 million. Shares of Avanir Pharma have jumped by over
8.20% in the last three sessions. So far this year, the stock has gained over
79.00%, hence outperforming the S&P 500. Moreover, the company's shares are
currently trading 3.56% below their 52-week high. A free report on AVNR can be
accessed by registering at:

http://www.AAAResearchReports.com/AVNR061913.pdf

Actavis Inc.'s stock saw a surge on Tuesday, closing at $125.67, up 0.58% from
its previous closing price. The company's shares traded between $124.44 and
$126.27 on total of 621,683 shares traded which is well below the daily
average volume of 2.06 million. Actavis' shares are now down by over 0.60% in
the last three trading sessions. Furthermore, the stock is currently trading
above its 50-day and 200-day moving averages. Register with AAA Research
Reports and download the research on ACT for free at:

http://www.AAAResearchReports.com/ACT061913.pdf

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE AAA Research Reports

Contact: Media Contact: AAAresearchreports.com, Phone #: +1-(646)-396-9126